Cellengene is biopharmaceutical company dedicated to the development for CAR-T therapy targeting refractory solid tumors. Our goal is to develop
"Off-the-Shelf" CAR-T therapy that can selectively attack cancer cells using immune cell derived from healthy people. In order to cure pancreatic cancer, we plan to use gammadelta T cell and induced pluripotent stem cell (iPSC) platform. Furthermore, we will be enable to cure ovarian cancer, mesothelioma and will become a global company to help many patients who are suffering from refractory cancers.
We belive next generation CAR-T therapy will give hope to many patients and lead them to have happier and healthier life.
CAR-T therapy is one of the immunotherapy, including genetically modifed T cell expressing unique receptor "Chimeric Antigenic Receptor" . This unique receptor binds to certain protein on patient's cancer cells and selectively attack them. In current situation, FDA approval were granted to 5 types of treatment targeting hematological malignancies, including “Kymriah” from Novartis and “Yescarta” from Gilead. There are many ongoing researches, developments and clinical stages on CAR-T therapy but no succeed case appears yet.
In general, there are two ways to manufacture CAR-T therapy. Autologous CAR-T is personalized therapy that does not incur GvHD. Because it is derived from patient's own cell and reinjected to the patient. However, manufacturing process takes at least 3 weeks and costs are very expensive. Allogenic CAR-T is universial therapy that require genetically engineering process and mass production is available. Manufacturing process takes approximately 1 week and costs are lower than autologous CAR-T production. Therefore, immediate injection is available for hundreds of patients.
Preventing GvHD and overcoming tumor microenvironment(TME) are key factors to develop allogenic CAR-T therapy. In order to overcome these certain problems, TCR is knockout using CRISPER/CAS9 gene editing technology and immune check receptor, PD-1, is knockdown to induce T cell activation and attack cancer cell continuously.
iPSC technology is capable of unlimiting T cell expansion and producing homogenous differentiated T cell. It provides high purity with massive amounts of production of allogenic T cell. Therefore, manufacturing cost is low and less-time consuming.
|category||Frequently asked question about this pages and delevery process while ordered post didn't arrive 7||admin||now||50|
|9||category||Good design.I will be glad if you see my latest work.||Jack||5 hour ago||175|
|8||category||awesome work..really very inspirational job.congrats||David James||3 days ago||534|
|7||category||Beautiful design and layout.. Great job||BaByliss||dev 22||51|
|6||category||Amazing work one really feels like in a stone age. Impressive!||Oliver Warren||dev 7||235|
|5||category||Unbelievable divat not dive project itself is awesome but it's presentation here... congratulations!||DIANA||nov 31||165|
|4||category||Excellent work! Great presentation!||Jett||nov 18||25|
|3||category||od design.I will be glad if you see my latest work.||Lincoln||nov 17||266|
|2||category||Beautiful design and layout.. Great job||Blaise||nov 13||369|
|1||category||Amazing work one really feels like in a stone age. Impressive!||Raphael||nov 4||16|
T. (+82) 2-966-2676
3rd Floor, Research Building, Institut Pasteur Korea 16 Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si,
Gyeonggido, Korea, 13488
Research Building Rm 204, Seoul Bio Hub
117-3 Hoegi-ro, Dongdaemun-gu, Seoul,
Republic of Korea, 02455
개인정보 수집 및 이용 동의 / 약관 보기